18F-FDG-PET/CT-measured parameters as potential predictors of residual disease after neoadjuvant chemoradiotherapy in patients with esophageal carcinoma

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorTUSTUMI, Francisco
dc.contributor.authorALBENDA, David Gutiérrez
dc.contributor.authorSALLUM, Rubens Antonio Aissar
dc.contributor.authorNAHAS, Sergio Carlos
dc.contributor.authorRIBEIRO JUNIOR, Ulysses
dc.contributor.authorBUCHPIGUEL, Carlos Alberto
dc.contributor.authorCECCONELLO, Ivan
dc.contributor.authorDUARTE, Paulo Schiavom
dc.date.accessioned2023-01-17T15:08:18Z
dc.date.available2023-01-17T15:08:18Z
dc.date.issued2022
dc.description.abstractAbstract Objective: To evaluate the maximum and mean standardized uptake values, together with the metabolic tumor value and the total lesion glycolysis, at the primary tumor site, as determined by 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (18F-FDG-PET/CT), performed before and after neoadjuvant chemoradiotherapy (nCRT), as predictors of residual disease (RD) in patients with esophageal cancer. Materials and Methods: The standardized uptake values and the volumetric parameters (metabolic tumor value and total lesion glycolysis) were determined by 18F-FDG-PET/CT to identify RD in 39 patients before and after nCRT for esophageal carcinoma. We used receiver operating characteristic curves to analyze the diagnostic performance of 18F-FDG-PET/CT parameters in the definition of RD. The standard of reference was histopathological analysis of the surgical specimen. Results: Eighteen patients (46%) presented RD after nCRT. Statistically significant areas under the curve (approximately 0.72) for predicting RD were obtained for all four of the variables evaluated after nCRT. Considering the presence of visually detectable uptake (higher than the background level) at the primary tumor site after nCRT as a positive result, we achieved a sensitivity of 94% and a specificity of 48% for the detection of RD. Conclusion: The use of 18F-FDG-PET/CT can facilitate the detection of RD after nCRT in patients with esophageal cancer.eng
dc.description.abstractResumo Objetivo: Avaliar os valores máximo e médio de captação padronizada, o valor metabólico do tumor e a glicólise total da lesão do local do tumor primário, medidos no estudo de 18F-FDG-PET/CT realizado antes e depois da quimiorradioterapia neoadjuvante (nQRT) em pacientes com câncer de esôfago, como preditores de doença residual (DR). Materiais e Métodos: Os valores máximo e médio de captação padronizada e os parâmetros volumétricos (valor metabólico do tumor e glicólise total da lesão) da 18F-FDG-PET/CT realizada em 39 pacientes antes e após a nQRT para carcinoma de esôfago foram avaliados para RD. Usamos curvas receiver operating characteristic (ROC) para analisar o desempenho diagnóstico dos parâmetros 18F-FDG-PET/CT na definição de RD. O estudo anatomopatológico foi utilizado como padrão ouro. Resultados: Dezoito pacientes (46%) apresentaram DR após a nQRT. Áreas estatisticamente significativas sob a curva ROC para predizer DR foram obtidas para as quatro variáveis nos estudos realizados após a nQRT, com áreas sob a curva ROC semelhantes em torno de 0,72. Considerando a presença de captação visualmente detectável (captação maior que o background) no local da lesão primária após a nQRT como resultado positivo, teríamos uma sensibilidade de 94% e uma especificidade de 48% para detecção de DR. Conclusão: A 18F-FDG-PET/CT pode ser útil para detectar a presença de doença neoplásica residual no câncer de esôfago após a nQRT.por
dc.description.indexPubMedeng
dc.identifier.citationRADIOLOGIA BRASILEIRA, v.55, n.5, p.286-292, 2022
dc.identifier.doi10.1590/0100-3984.2021.0135
dc.identifier.issn1678-7099
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/50949
dc.language.isoengpor
dc.publisherPublicação do Colégio Brasileiro de Radiologia e Diagnóstico por Imagemeng
dc.relation.ispartofRadiologia Brasileira
dc.rightsopenAccesseng
dc.rights.holderCopyright Publicação do Colégio Brasileiro de Radiologia e Diagnóstico por Imagemeng
dc.subjectEsophageal neoplasmseng
dc.subjectNeoadjuvant therapyeng
dc.subjectPositron-emission tomographyeng
dc.subjectNuclear medicineeng
dc.subjectNeoplasias esofágicaseng
dc.subjectTerapia neoadjuvanteeng
dc.subjectTomografia por emissão de pósitronseng
dc.subjectMedicina nucleareng
dc.subjectNeoplasias esofágicas
dc.subjectTerapia neoadjuvante
dc.subjectTomografia por emissão de pósitrons
dc.subjectMedicina nuclear
dc.subject.wosRadiology, Nuclear Medicine & Medical Imagingeng
dc.title18F-FDG-PET/CT-measured parameters as potential predictors of residual disease after neoadjuvant chemoradiotherapy in patients with esophageal carcinomaeng
dc.title.alternative18F-FDG-PET/CT após quimiorradioterapia neoadjuvante em pacientes com carcinoma de esôfago como potencial preditor de doença residualeng
dc.title.alternative18F-FDG-PET/CT após quimiorradioterapia neoadjuvante em pacientes com carcinoma de esôfago como potencial preditor de doença residual
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.citation.scopus3
hcfmusp.contributor.author-fmusphcFRANCISCO TUSTUMI
hcfmusp.contributor.author-fmusphcDAVID ALBERTO GUTIERREZ ALBENDA
hcfmusp.contributor.author-fmusphcRUBENS ANTONIO AISSAR SALLUM
hcfmusp.contributor.author-fmusphcSERGIO CARLOS NAHAS
hcfmusp.contributor.author-fmusphcULYSSES RIBEIRO JUNIOR
hcfmusp.contributor.author-fmusphcCARLOS ALBERTO BUCHPIGUEL
hcfmusp.contributor.author-fmusphcIVAN CECCONELLO
hcfmusp.contributor.author-fmusphcPAULO SCHIAVOM DUARTE
hcfmusp.description.beginpage286
hcfmusp.description.endpage292
hcfmusp.description.issue5
hcfmusp.description.volume55
hcfmusp.origemsciELO
hcfmusp.origem.pubmed36320366
hcfmusp.origem.scieloSCIELO:S0100-39842022000500286
hcfmusp.origem.scopus2-s2.0-85138300563
hcfmusp.relation.referenceArnett ALH, 2017, J THORAC ONCOL, V12, P121, DOI 10.1016/j.jtho.2016.08.136eng
hcfmusp.relation.referenceBerger AC, 2005, J CLIN ONCOL, V23, P4330, DOI 10.1200/JCO.2005.05.017eng
hcfmusp.relation.referenceButof R, 2015, J NUCL MED, V56, P1150, DOI 10.2967/jnumed.115.155309eng
hcfmusp.relation.referenceCerfolio RJ, 2004, ANN THORAC SURG, V78, P1903, DOI 10.1016/j.athoracsur.2004.06.102eng
hcfmusp.relation.referenceChoi Y, 2022, EUR J NUCL MED MOL I, V49, P751, DOI 10.1007/s00259-021-05487-weng
hcfmusp.relation.referenceElimova E, 2015, EUR J CANCER, V51, P2545, DOI 10.1016/j.ejca.2015.07.044eng
hcfmusp.relation.referenceElliott JA, 2014, BRIT J SURG, V101, P1702, DOI 10.1002/bjs.9670eng
hcfmusp.relation.referenceHabr-Gama A, 2004, ANN SURG, V240, P711, DOI 10.1097/01.sla.0000141194.27992.32eng
hcfmusp.relation.referenceHatt M, 2011, EUR J NUCL MED MOL I, V38, P1191, DOI 10.1007/s00259-011-1755-7eng
hcfmusp.relation.referenceHeneghan HM, 2016, ANN SURG, V264, P831, DOI 10.1097/SLA.0000000000001902eng
hcfmusp.relation.referenceHofheinz F, 2019, EUR J NUCL MED MOL I, V46, P1485, DOI 10.1007/s00259-019-04307-6eng
hcfmusp.relation.referenceHong JH, 2016, J KOREAN MED SCI, V31, P39, DOI 10.3346/jkms.2016.31.1.39eng
hcfmusp.relation.referenceJayachandran P, 2012, INT J RADIAT ONCOL, V84, P471, DOI 10.1016/j.ijrobp.2011.12.029eng
hcfmusp.relation.referenceLemarignier C, 2014, EUR J NUCL MED MOL I, V41, P2008, DOI 10.1007/s00259-014-2839-yeng
hcfmusp.relation.referenceLi YM, 2015, INT J CLIN EXP MED, V8, P10947eng
hcfmusp.relation.referenceMaffione AM, 2015, AM J ROENTGENOL, V204, P1261, DOI 10.2214/AJR.14.13210eng
hcfmusp.relation.referenceMcLoughlin JM, 2008, J AM COLL SURGEONS, V206, P879, DOI 10.1016/j.jamcollsurg.2007.12.027eng
hcfmusp.relation.referenceMolena D, 2014, DIS ESOPHAGUS, V27, P355, DOI 10.1111/dote.12126eng
hcfmusp.relation.referenceMota FC, 2018, INT J SURG, V54, P176, DOI 10.1016/j.ijsu.2018.04.053eng
hcfmusp.relation.referenceOdawara S, 2018, EUR J RADIOL, V101, P65, DOI 10.1016/j.ejrad.2018.02.009eng
hcfmusp.relation.referenceOtt K, 2006, J CLIN ONCOL, V24, P4692, DOI 10.1200/JCO.2006.06.7801eng
hcfmusp.relation.referenceRice TW, 2017, ANN CARDIOTHORAC SUR, V6, P119, DOI 10.21037/acs.2017.03.14eng
hcfmusp.relation.referenceSchmidt M, 2009, EUR J NUCL MED MOL I, V36, P735, DOI 10.1007/s00259-008-1011-yeng
hcfmusp.relation.referenceTakeda FR, 2020, ANN SURG ONCOL, V27, P1241, DOI 10.1245/s10434-019-07967-8eng
hcfmusp.relation.referenceTustumi F, 2021, NUCL MED COMMUN, V42, P437, DOI 10.1097/MNM.0000000000001347eng
hcfmusp.relation.referencevan Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088eng
hcfmusp.relation.referenceWieder HA, 2004, J CLIN ONCOL, V22, P900, DOI 10.1200/JCO.2004.07.122eng
hcfmusp.relation.referenceZhang H, 2014, INT J RADIAT ONCOL, V88, P195, DOI 10.1016/j.ijrobp.2013.09.037eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublicationb198d885-85d1-4da2-bf9f-de22e2308c6c
relation.isAuthorOfPublicationc0eb0303-d05a-4faf-a5ea-49ca7cff0032
relation.isAuthorOfPublicationd1507f94-6ef4-4ca9-8784-b1499b5dfae6
relation.isAuthorOfPublication0ab50572-97be-4931-8ade-d2f681c8b19e
relation.isAuthorOfPublicationa4bfdcf9-89f7-472f-9936-aa817156faad
relation.isAuthorOfPublication6fcbbc21-1ba0-4023-a2cd-0e709b22f5c3
relation.isAuthorOfPublicatione0a211ed-1f62-4700-bf7b-a7cd39218361
relation.isAuthorOfPublicationf5dbbb8c-c66c-4c03-88a2-58cb059b893a
relation.isAuthorOfPublication.latestForDiscoveryb198d885-85d1-4da2-bf9f-de22e2308c6c
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_TUSTUMI_18FFDGPETCTmeasured_parameters_as_potential_predictors_of_residual_disease_2022.PDF
Tamanho:
1.43 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24
Carregar mais